Exelon, Aricept and Reminyl would now be made available to patients with mild disease, as well as moderate patients. Alzheimer Scotland said patients north of the border had fared better in accessing the drugs as doctors had been allowed to make their own judgments.
FULL ARTICLE AT The Scotsman